Slow approvals put India’s drug trials industry at risk

Slower government approval for testing new medicines is threatening India’s aspirations to be a fast-growing, low-cost hub for clinical trials, and has prompted some drugs firms to shift operations elsewhere, adding to their costs.

While India’s drug regulator and the health ministry’s medical research body deny any slowdown, interviews by Reuters with pharmaceutical companies, lobby groups, industry watchers and healthcare activists tell a different story.

via Business feed http://www.scmp.com/business/companies/article/1149349/slow-approvals-put-indias-drug-trials-industry-risk